HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study)

Files in This Item:

The file(s) associated with this item can be obtained from the following URL: https://doi.org/10.1016/j.diabres.2021.109069


Title: Lowering of blood pressure and pulse rate by switching from DPP-4 inhibitor to luseogliflozin in patients with type 2 diabetes complicated with hypertension: A multicenter, prospective, randomized, open-label, parallel-group comparison trial (LUNA study)
Authors: Hashimoto-Kameda, Reina Browse this author
Cho, Kyu Yong Browse this author
Nomoto, Hiroshi Browse this author
Nakamura, Akinobu Browse this author
Omori, Kazuno Browse this author
Nagai, So Browse this author
Edagawa, Sachiko Browse this author
Kawata, Shinichiro Browse this author
Takeuchi, Jun Browse this author
Kameda, Hiraku Browse this author
Kurihara, Yoshio Browse this author
Aoki, Shin Browse this author
Atsumi, Tatsuya Browse this author →KAKEN DB
Miyoshi, Hideaki Browse this author →KAKEN DB
Keywords: inhibitor
Type 2 diabetes
Hypertension
Sodium-glucose cotransporter-2
Issue Date: Oct-2021
Publisher: Elsevier
Journal Title: Diabetes research and clinical practice
Volume: 180
Start Page: 109069
Publisher DOI: 10.1016/j.diabres.2021.109069
Abstract: Aims: Sodium-glucose cotransporter-2 inhibitor (SGLT2i) reduces clinic blood pressure (BP), but the effects on BP circadian rhythm remain unclear. The present study aimed to determine the nighttime antihypertensive effect of SGLT2i compared with dipeptidyl peptidase-4 inhibitor (DPP-4i) in patients with type 2 diabetes and hypertension. Materials and Methods: In this randomized, open-label, parallel-group trial, patients treated with DPP-4i were either switched to luseogliflozin 2.5 mg/day (Luseo group; n = 30) or continued DPP-4i (DPP-4i group; n = 26). The patients undertook 24-h ambulatory BP monitoring before and 8 weeks after the group allocation. The primary endpoint was mean change in nighttime systolic BP (SBP). Results: Nighttime SBP, as well as daytime SBP, was significantly reduced in the Luseo group compared with the DPP-4i group (nighttime,-4.0 +/- 11.4 vs. 3.6 +/- 10.7 mmHg, P = 0.01; day time,-4.4 +/- 10.9 vs. 3.7 +/- 11.9 mmHg, P = 0.01). Similarly, nighttime pulse rate (PR) was significantly reduced in the Luseo group (-2.0 +/- 4.8 vs. 0.9 +/- 4.8 bpm, P = 0.03). The proportion of patients with abnormal BP circadian rhythms (non-dipper pattern plus riser pattern) was significantly lower in the Luseo group (36.6% vs. 56.7%, P < 0.05). Conclusions: Switching from DPP-4i to luseogliflozin decreased nighttime SBP and PR; moreover, BP circadian rhythm was improved. (C) 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Type: article
URI: http://hdl.handle.net/2115/83964
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Export metadata:

OAI-PMH ( junii2 , jpcoar_1.0 )

MathJax is now OFF:


 

 - Hokkaido University